News Summary
PositiveNovartis reported Q2 2026 results with an EPS beat (+$0.07 vs. consensus) and returned to net sales growth (3% USD) despite Entresto generic headwinds, with management affirming mid-single digit growth guidance for H2 2026. The pipeline showed concrete progress with Fabhalta earning full FDA approval for IgA nephropathy and LEQVIO gaining meaningful Medicare market share (23.3%), while CEO Narasimhan reaffirmed commitment and signaled positive trial readouts expected in H2 2026.
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Point72 | Steve Cohen | 106K | +106K | $17M | <0.1% | — | NEW |
| Glenview Capital | Larry Robbins | 87K | +87K | $14M | 0.3% | — | NEW |
| Maverick Capital | Lee Ainslie | 28K | +13K | $4M | <0.1% | +82% | Existing |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where NVS ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #37 of this fund's book
- 34ELEVANCE HEALTH INC FORMERLY$26M
- 35MICROCHIP TECHNOLOGY INC.$24M
- 36BRUKER CORP$15M
- 37NOVARTIS AG$14M
- 38DIGITALOCEAN HLDGS INC$13M
- 39PRIMO BRANDS CORPORATION$10M
- 40BOSTON SCIENTIFIC CORP$5M
Values are quarter-end position sizes. Shown only for funds where NVS ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-31 | 2026-07-21 | ↗ |
| Alan Armstrong | senate | — | BUY | $15,001 - $50,000 | 2026-03-30 | 2026-07-21 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures.